Sponsor Pipeline

NextCure, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
2
Recruiting
7
Disease Areas
7
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-14 NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants…		 critical Trial terminated
2026-08-14 NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants…		 critical Trial terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.
2026-08-14 NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants…		 Primary endpoint(s) modified
2026-08-14 NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants…		 date change Primary completion moved earlier: 2025-07 -> 2025-04-30
2026-08-14 NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants…		 date change Completion moved earlier: 2025-11 -> 2025-04-30
2026-07-29 NCT06792552
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors		 Primary endpoint(s) modified
2026-07-29 NCT06792552
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors		 Enrollment increased: 414 -> 738 participants
Active Trials by Phase
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1
NCT06774963 A Phase 1 Study of LNCB74 in Advanced Solid Tumors Ovarian Cancer Recruiting
NCT06792552 A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors Advanced Solid Tumors Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2) Ovarian Cancer (2) Breast Cancer (1) Endometrial Cancer (1) Cholangiocarcinoma (1) Kidney Cancer (1)
Get alerts when NextCure, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free